The role of fecal biomarkers in predicting inflammatory bowel diseases

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Fecal biomarkers (FBM) reflect the severity of inflammation of the intestinal mucosa to a greater extent compared with similar blood serum markers. Serum markers can change for many reasons, but local inflammation in the intestine does not always correspond to the systemic inflammatory response detected in the blood. To date, many FBMs have been identified, but only a few have been thoroughly studied in children. This article examines in more detail the following promising markers: calprotectin, S100A12, M2-pyruvate kinase, osteoprotegerin, myeloperoxidases, HMGB 1, matrix metalloproteinases, and the currently recommended fecal calprotectin. At the moment, there is no single universal marker that would have high sensitivity, specificity and prognostic ability in both Crohn’s disease (CD) and ulcerative colitis (UC).

Texto integral

Acesso é fechado

Sobre autores

Aelita Kamalova

Kazan State Medical University, Department of Hospital Pediatrics; Children’s Republican Clinical Hospital

Autor responsável pela correspondência
Email: aelitakamalova@gmail.com
ORCID ID: 0000-0002-2957-680X

Dr. Sci. (Med.), Professor at the Department of Hospital Pediatrics

Rússia, Kazan; Kazan

G. Garina

Kazan State Medical University, Department of Hospital Pediatrics

Email: aelitakamalova@gmail.com
ORCID ID: 0000-0002-4333-8779
Rússia, Kazan

M. Khanafina

Kazan State Medical University, Department of Hospital Pediatrics

Email: aelitakamalova@gmail.com
ORCID ID: 0009-0009-0814-0773
Rússia, Kazan

I. Valeeva

Kazan State Medical University, Department of Hospital Pediatrics

Email: aelitakamalova@gmail.com
Rússia, Kazan

Bibliografia

  1. De Souza, Fiocchi C., Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14(12):739–49. doi: 10.1038/nrgastro.
  2. Schechte A., Griffiths C., Gana J.C., et al. Early endoscopic, laboratory and clinical predictors of poor disease course in paediatric ulcerative colitis. Gut. 2015;64:580–88. doi: 10.1136/gutjnl-2014-306999.
  3. Turner D., Griffiths A.M., Veerman G., et al. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab. Clin Gastroenterol Hepatol. 2013;11:1460–65. doi: 10.1016/j.cgh.2013.04.049.
  4. Oliva S., Thomson M., de Ridder L., et al. Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the Espghan. J Pediatr Gastroenterol Nutr. 2018;67:414–30. doi: 10.1097/MPG.0000000000002092.
  5. Roseth A., Aadland E., Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004;39:1017–20.
  6. Pang T., Leach S.T., Katz T., et al. Fecal biomarkers of intestinal health and disease in children. Front Pediatr. 2018;67:414–30. doi: 10.3389/fped.2014.00006.
  7. Sherwood R.A. Faecal markers of gastrointestinal inflammation. J Clin Pathol. 2012;65:981–85. doi: 10.1136/jclinpath-2012-200901.
  8. Langhorst J., Elsenbruch S., Koelzer J., et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162–69. doi: 10.1111/j.1572-0241.2007.01556.x.
  9. Lopez R.N., Leach S.T., Lemberg D.A., et al. Faecal biomarkers in inflammatory bowel disease. Am J Gastroenterol Hepatol. 2016;32:577–82. doi: 10.1111/jgh.13611.
  10. Ruemmele F.M., Veres G., Kolh K.L., et al. European Crohn’s and Colitis Organisation, European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179–207. doi: 10.1016/j.crohns.2013.06.001.
  11. Turner D., Ruemmele F.M., Orlanski-Meyer T., et al. Management of paediatric ulcerative colitis, part 2: acute severe colitis-an evidence based Consensus Guideline From the European Crohn’s and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67:292–310. doi: 10.1097/MPG.0000000000002036.
  12. Van Rheenen P.F., Aloi M., Assa A., et al. The medical management of paediatric Crohn’s disease: an ECCO-ESPGHAN Guideline Update. J Crohn’s Colitis. 2020;15:171–94. doi: 10.1093/ecco-jcc/jjaa161.
  13. Kolho K., Alfthan H. Concentration of fecal calprotectin in 11,255 children aged 0-18 years. Scand J Gastroenterol. 2020;55:1024–27. doi: 10.1080/00365521.
  14. Koninckx C.R., Donat E., Benninga M.A., et al. The Use of Fecal Calprotectin Testing in Paediatric Disorders: A Position Paper of the European Society for Paediatric Gastroenterology and Nutrition Gastroenterology Committee. J Pediatr Gastroenterol Nutr. 2021;72:617–40. doi: 10.1097/MPG.0000000000003046.
  15. Walker G.J., Chanchlani N., Thomas A., et al. Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study. Arch Dis Child. 2020;105(10):957–63. doi: 10.1136/archdischild-2019-317823.
  16. Ливзан М.А., Долгих Т.И., Лялюкова Е.А. Фекальный кальпротектин в комплексной диагностике заболеваний кишечника. Экспериментальная и клиническая гастроэнтерология. 2013:12:83–6. [Livzan M.A., Dolgikh T.I., Lyalukova E.A. Fecal calprotectin in the complex diagnosis of intestinal diseases. Exp Clin Gastroenterol. 2013:12:83–6. (In Russ.)].
  17. Day A.S., Ehn M., Gearry R.B., et al. Fecal S100A12 in healthy infants and children. Disease Markers.2013;35:295–99. doi: 10.1155/2013/873582.
  18. Leach S.T., Yang Z., Messina I., et al. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol. 2007;42:1321–31. doi: 10.1080/00365520701416709.
  19. Foell D., Wittkowski H., et al. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J Pathol. 2007;216:183–92. doi: 10.1002/path.2394.
  20. Kaiser T., Langhorst J.., Wittkowski H., et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut. 2007;56:1706–13. doi: 10.1136/gut.2006.113431.
  21. Dabritz J., Langhorst J., Lugering A., et al. Improving relapse prediction in inflammatory bowel disease by neutrophilderived S100A12. Inflammatory Bowel Diseases. 2013;19:1130–38. doi: 10.1097/MIB.0b013e318280b1cd.
  22. Kyle B.D., Agbor T.A., Sharif S., et al. Fecal calprotectin, CRP and leucocytes in IBD patients: comparison of biomarkers with biopsy results. J Can Assoc Gastroenterol. 2021;4:84–90. doi: 10.1093/jcag/gwaa009.
  23. De Jong N.S., Leach S.T., Day A.S. Fecal S100A12: a novel noninvasive marker in children with Crohn’s disease. Inflamm Bowel Dis. 2006;12:566–72. doi: 10.1097/MIB.0b013e318280b1cd.
  24. Czub E., Herzig K.H., Szaflarska-Popawska A., et al. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease. Scand J Gastroenterol. 2007;42:1147–50. doi: 10.1080/00365520701320513.
  25. Judd T.A., Day A.S., Lemberg D.A., et al. Update of fecal markers of inflammation in inflammatory bowel disease. J Gastroenterol Hepatol. 2011;26:1493–99. doi: 10.1111/j.1440-1746.
  26. Leach S.T., Day A.S., Messenger R., et al. Fecal Markers of Inflammation and Disease Activity in Pediatric Crohn Disease: Results from the ImageKids Study. J Pediatr Gastroenterol Nutr 2020;70(5):580–585. doi: 10.1097/MPG.0000000000002615.
  27. Chung-Faye G., Hayee B., Maestranzi S., et al. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation. Inflamm Bowel Dis. 2007;13:1374–78. doi: 10.1002/ibd.20214.
  28. Turner D., Leach S.T., Mack D., et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010;59:1207–12. doi: 10.1136/gut.2010.211755.
  29. Beaugerie L., Svrcek M., Seksik P., et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013;145:166–75. doi: 10.1053/j.gastro.2013.03.044.
  30. Olen O., Erichsen R., Sachs M.C., et al. Colorectal cancer in Crohn’s disease: a Scandinavian population-based cohort study. Lancet Gastroenterol Hepatol. 2020:5:475–84. doi: 10.1016/S2468-1253(20)30005-4.
  31. Chaparro M., Garre A., Ricart E., et al. Differences between childhood-and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU. Aliment Pharmacol Ther. 2019;49:419–28. doi: 10.1111/apt.15114.
  32. Olen O., Askling J., Sachs M.C., et al. Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964–2014. BMJ. 2017;358:j3951. doi: 10.1136/bmj.j3951
  33. Hardt P.D., Mazurek S., Toepler M., et al. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer. 2004;91:980–84. doi: 10.1038/sj.bjc.6602033
  34. Duvoisin G., Lopez R.N., Day A.S. Novel biomarkers and the future potential of biomarkers in inflammatory bowel disease. Mediators of Inflamm. 2017;2017:1936315. doi: 10.1155/2017/1936315.
  35. Sylvester F.A., Turner D., Draghi A. 2nd et al. Fecal osteoprotegerin may guide the introduction of second-line therapy in hospitalized children with ulcerative colitis. Inflammatory Bowel Diseases. 2011;17:1726–30. doi: 10.1002/ibd.21561.
  36. Nahidi L., Leach S.T., Sidler M.A., et al. Osteoprotegerin in pediatric Crohn’s disease and the effects of exclusive enteral nutrition. Inflamm Bowel Dis. 2011;17:516–53. doi: 10.1002/ibd.21361.
  37. Gordon, R.J., Gordon, C.M. Bone Health in Pediatric Patients with IBD: What Is New? Curr Osteoporos Rep. 2021;19:429–35. doi: 10.1007/s11914-021-00691-x.
  38. Peterson C.G., Eklund E., Taha Y., et al. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol. 2002;97:1755–62. doi: 10.1111/j.1572-0241.
  39. Newell K.J., Matrisian L.M., Driman D.K. Matrilysin (matrix metalloproteinase-7) expression in ulcerative colitisrelated tumorigenesis. Molecular Carcinogenesis. 2002;34:59–63. doi: 10.1002/mc.10049.
  40. Coskun M., Bjerrum J.T., Seidelin J.B., et al. MiR-20b, miR-98, miR-125b-1, and let-7e as new potential diagnostic biomarkers in ulcerative colitis. World J Gastroenterol. 2013;19:4289–99. doi: 10.3748/wjg.v19.i27.4289.
  41. Vitali R., Stronati L., Negroni A., et al. Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease. Am J Gastroenterol. 2011;106:2029–40. doi: 10.1038/ajg.2011.231.
  42. Palone F., Vitali R., Cucchiara S., et al. Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:1448–57. doi: 10.1097/MIB.0000000000000113.
  43. Medina C., Radomski M.W. Role of matrix metalloproteinases in intestinal inflammation. The Journal of Pharmacology and Experimental Therapeutics. 2006;318:933–38. doi: 10.1124/jpet.106.103465.
  44. von Lampe B., Barthel B., Coupland S.E., et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut. 2000;47:63–7. doi: 10.1136/gut.47.1.63.
  45. Gao Q., Meijer M.J., Kubben F.J., et al. Expression of matri metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis. 2005;37:584–92. doi: 10.1016/j.dld.2005.02.011.
  46. Farkas K., Sarodi Z., Balint A., et al. The diagnostic value of a new fecal marker, matrix metalloprotease-9, in different types of inflammatory bowel diseases. J Crohns Colitis. 2015;9:231–37. doi: 10.1093/ecco-jcc/ jjv005.
  47. Kolho K.L., Sipponen T., Valtonen E., Savilahti E. Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease. Int J Colorectal Dis. 2014;29:43–50. doi: 10.1007/s00384-013-1775-9.
  48. Maronek M., Marafini I., Gardlik R., et al. Metalloproteinases in Inflammatory Bowel Diseases. J Inflamm Res. 2021;14:1029–41. doi: 10.2147/JIR.S288280.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2024

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies